Kuriyama K, Murakami K, Sugiura K, Sakui S, et al. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial. Vaccine 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
PMID: 38129286